BioSpace News Archive

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced the pricing of its upsized underwritten public offering of 4,755,000 shares of its common stock at a public offering price of $47.00 per share.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what Acumen believes to be a key underlying cause of Alzheimer’s disease, announced the pricing of its upsized initial public offering of 9,999,999 shares of common stock at a public offering price of $16.00 per share.

The increased efforts of pharmaceutical companies for the development of novel therapies to treat infectious diseases will positively influencing market growth.

Abbott (NYSE: ABT) today announced its XIENCE family of stents has received U.S. Food and Drug Administration (FDA) approval for one-month (as short as 28 days) DAPT labeling for high bleeding risk (HBR) patients

Vivalink, a leading provider of connected healthcare solutions known for its unique medical wearable sensor data platform, today announces a newly enhanced temperature and cardiac electrocardiogram (ECG) monitor

South Korean artificial intelligence developer, VUNO Inc., announced a partnership with Samsung Electronics Co., Ltd., global medical device company to incorporate its AI-powered chest X-ray diagnostic solution, VUNO Med®-Chest X-ray™, into Samsung’s premium mobile digital X-ray system, GM85.

Vivera Pharmaceuticals, Inc. and diagnostic testing distributor, Areum Bio LLC, today announce their channel partnership to expand the distribution of Access Bio, Inc.'s CareStart ™ COVID-19 Rapid Antigen Test and line of products granted FDA Emergency Use Authorization (EUA).

PharmaJet today announced that patient enrollment has started for the phase 1 trial in Australia using its Needle-free Injection Systems to deliver a vaccine against SARS-CoV-2.

Scopus BioPharma Inc. today announced the acquisition of Los Angeles-based Olimmune Inc.

Wise Therapeutics (Wise), a developer of game-based digital therapeutics including Personal Zen , and Soterix Medical jointly announced the results of their collaborative study, published in Frontiers in Neuroergonomics.